“Historic” cisplatin shortage leaves oncologists guessing whether they will have enough to treat the next patient

Dual-targeted therapies + chemo shows high response rates in BRAF-mutated metastatic CRC, phase III trial shows

Patients with metastatic colorectal cancer harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies Braftovi(encorafenib) and Erbitux(cetuximab) plus a mFOLFOX6 chemotherapy regimen, according to results from the phase III BREAKWATER trial led by researchers at the University of Texas MD Anderson Cancer Center.

January 31, 2025

Vol.51 No.04

Conversation with The Cancer Letter

After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency

In 1999, Richard Pazdur, a GI oncologist at MD Anderson, saw an FDA recruitment ad in The New England Journal of Medicine. The agency was looking for a director of the FDA Division of Oncology Drug Products.

Hair growth drug safe at low doses for breast cancer patients, retrospective cohort study shows

A retrospective cohort study in women with breast cancer suggests that low oral doses of minoxidil taken during or after cancer treatment appear to regrow hair in most patients without causing any serious heart-related side effects that require additional therapies or hospitalization.

January 10, 2025

Vol.51 No.01

Clinical Roundup

MammaPrint test demonstrates utility in predicting chemotherapy benefit over five years

Agendia Inc. announced it will be presenting new data from the Real-World Data Registry, FLEX, demonstrating MammaPrint’s ability to predict chemotherapy benefit in patients with HR+HER2- early-stage breast cancer. The findings will be presented at the San Antonio Breast Cancer Symposium 2024. The MammaPrint test analyzes the 70 most important genes associated with breast cancer recurrence.

December 13, 2024

Vol.50 No.46

Clinical Roundup

High-dose chemo + autologous stem cell therapy demonstrates no benefit in MRD-negative mantle-cell lymphoma, phase III study shows

Timothy S. Fenske, Medical College of Wisconsin, presented findings from the ECOG-ACRIN phase III study EA4151, investigating rituximab with or without stem cell transplant in patients With minimal residual disease-negative mantle cell lymphoma in first complete remission, at the 66th ASH Annual Meeting and Exposition in San Diego.

December 13, 2024

Vol.50 No.46

Clinical Roundup

NYU study details how cancer cells evade chemotherapy

Laboratory experiments with cancer cells reveal two ways in which tumors evade chemotherapy drugs designed to starve and kill them, a new study in Nature Metabolism shows.

December 06, 2024

Vol.50 No.45

“Historic” cisplatin shortage leaves oncologists guessing whether they will have enough to treat the next patient

YOU MAY BE INTERESTED IN

Dual-targeted therapies + chemo shows high response rates in BRAF-mutated metastatic CRC, phase III trial shows

After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency

Hair growth drug safe at low doses for breast cancer patients, retrospective cohort study shows

MammaPrint test demonstrates utility in predicting chemotherapy benefit over five years

High-dose chemo + autologous stem cell therapy demonstrates no benefit in MRD-negative mantle-cell lymphoma, phase III study shows

NYU study details how cancer cells evade chemotherapy

Renew today!

Subscriber content

Never miss an issue!

Login